Floatz logo

Piracetam

Acute Ischaemic Middle Cerebral Artery Stroke

UCB S.A. - Pharma SectorSmall moleculePhase 4 / ApprovedDormant
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Acute Ischaemic Middle Cerebral Artery Stroke cohort.

Asset / SponsorPhaseRating
Recombinant Human Plasminogen Activator
SOS Attaque Cérébrale
Phase 4BB
Recombinant Human Erythropoietin Alfa
Max-Planck-Institute of Experimental Medicine
Phase 2/3B
PHYSIOLOGIC SODIUM CHLORIDE SOLUTION
Max-Planck-Institute of Experimental Medicine
Phase 2/3B
Human Placenta-Derived Cells Pda001-
Celularity Incorporated
Phase 2CCC
Auto-Cd34+ Cells
Imperial College London
Phase 1/2CCC

View all 10 →

Same molecule, other indications

Piracetam is also rated in:

dementiaDormant
CC
Indicative ·
45 / 100
View asset →
physiological malfunction arising from mental factorDormant
CC
Indicative ·
45 / 100
View asset →
anxiety disorderDormant
CC
Indicative ·
45 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →